A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Transplantation Direct

Volumn 1, Issue 2, 2015, Pages E8-

  Shigematsu, Akio ^l   Ozawa, Yukiyasu ^a   Onizuka, Makoto ^b   Fujisawa, Shin ^c   Suzuki, Ritsuro ^d   Atsuta, Yoshiko ^d   Hatanaka, Kazuo ^e   Masuko, Masayoshi ^f   Ito, Toshiro ^g   Kobayashi, Naoki ^h   Kato, Jun ⁱ   Miyamura, Koichi ^a   Fukuda, Takahiro ^j   Morishima, Yasuo ^k   Imamura, Masahiro ^h  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e WAKAYAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^g SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAPPORO HOKUYU HOSPITAL   (Japan)

ⁱ KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NATIONAL CANCER CENTER HOSPITAL   (Japan)

^k AICHI CANCER CENTER HOSPITAL   (Japan)

^l HOKKAIDO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85130207470     PISSN: None     EISSN: 23738731     Source Type: Journal    
DOI: 10.1097/TXD.0000000000000514     Document Type: Article

References (35)

1. Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123.
2. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyperCVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547.
3. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;99:863.
4. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760.
5. Moorman AV, Harrison CJ, Buck GA, et al. For the Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189.
6. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532.
7. Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006;106:2657.
8. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006;12:1.
9. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005;90:1346.
10. Labar B, Suciu S, Zittoun R, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients
11. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075.
12. Toubai T, Tanaka J, Mori A, et al. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies. Clin Transplant 2004;18:552.
13. Shigematsu A, Kondo T, Yamamoto S, et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2008;14:568.
14. Shigematsu A, Tanaka J, Suzuki R, et al. Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Int J Hematol 2001;94:463.
15. Atsuta Y, Suzuki R, Yoshimi A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007;86:269.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825.
17. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250.
18. Giralt SA, LeMaistre CF, Vriesendorp HM, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 1994;12:1923.
19. Yau JC, LeMaistre CF, Andersson BS, et al. Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. Am J Hematol 1992;41:40.
20. Petersen FB, Buckner CD, Appelbaum FR, et al. Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow trans-plantation in patients with advanced hematological malignancies: a phase 1 study. Bone Marrow Transplant 1992;10:83.
21. Brown RA, Wolff SN, Fay JW, et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 1995;85:1391.
22. Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced stage hematological malignancies. Biol Blood Marrow Transplant 1997;3:324.
23. Duerst RE, Horan JT, Liesveld JL, et al. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. Bone Marrow Transplant 2000;25:489.
24. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALLXII/ECOG E2993). Blood 2008;111:1827.
25. Spitzer TR, Peters C, Ortlieb M, et al. Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. Int J Radiat Oncol Biol Phys 1994;29:39.
26. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028.
27. Dombret H, Gabert J, Boiron JM, et al. Groupe d'Etude et de Traitement de la Leucemie Aigue Lymphoblastique de l'Adulte (GET-LALA Group). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia–results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357.
28. Doney K, Hagglund H, Leisenring W, et al. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2003; 9:472.
29. Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant. 1991;7:453.
30. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012: http://www.cibmtr.org.
31. The Japan Society for Hematopoietic Cell Transplantation (JSHCT). Annual report of nationwide survey 2012: JSHCT Data Center, Nagoya, Japan, 2013. http://www.jshct.com/report_recent/.
32. Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006;12:438.
33. Slater LM, Sweet P, Stupecky M, et al. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD8 T-lymphocytes. Clin Immunol Immunopathol 1995;75:239.
34. Slater LM, Stupecky M, Sweet P, et al. Etoposide induction of tumor immunity in Lewis lung cancer. Cancer Chemother Pharmacol 2001; 48:327.
35. Slater LM, Stupecky M, Sweet P, et al. Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16. Leuk Res 2002;26:203.